High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand

Cancer Letters

Volumn 239, Issue 2, 2006, Pages 292-297

  Sriuranpong, V ^a   Chantranuwat, C ^a   Huapai, N ^b   Chalermchai, T ^a   Leungtaweeboon, K ^a   Lertsanguansinchai, P ^a   Voravud, N ^a   Mutirangura, A ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Adenocarcinoma; EGFR; Gefitinib; Lung cancer; Mutation; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; HUMAN; LUNG ADENOCARCINOMA; MALE; MUTATION RATE; NUCLEOTIDE SEQUENCE; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RACE DIFFERENCE; THAILAND;

ADENOCARCINOMA; AMINO ACID SEQUENCE; BASE SEQUENCE; EXONS; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE HOMOLOGY, AMINO ACID; THAILAND;

EID: 33745699228     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.08.029     Document Type: Article

References (21)

1. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2 (2001) 127-137
2. Scagliotti G.V., Selvaggi G., Novello S., and Hirsch F.R. The biology of epidermal growth factor receptor in lung cancer. Clin. Cancer Res. 10 (2004) 4227s-4232s
3. Sriuranpong V., Park J.I., Amornphimoltham P., Patel V., Nelkin B.D., and Gutkind J.S. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 63 (2003) 2948-2956
4. Herbst R.S., Maddox A.M., Rothenberg M.L., Small E.J., Rubin E.H., Baselga J., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20 (2002) 3815-3825
5. Rusch V., Baselga J., Cordon-Cardo C., Orazem J., Zaman M., Hoda S., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53 (1993) 2379-2385
6. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J. Am. Med. Assoc. 290 (2003) 2149-2158
7. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21 (2003) 2237-2246
8. Fuster L.M., and Sandler A.B. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clin. Lung. Cancer 6 Suppl. 1 (2004) S24-S29
9. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 22 (2004) 1103-1109
10. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 22 (2004) 785-794
11. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 22 (2004) 777-784
12. Parra H.S., Cavina R., Latteri F., Zucali P.A., Campagnoli E., Morenghi E., et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br. J. Cancer 91 (2004) 208-212
13. Cappuzzo F., Gregorc V., Rossi E., Cancellieri A., Magrini E., Paties C.T., et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J. Clin. Oncol. 21 (2003) 2658-2663
14. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
15. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
16. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101 (2004) 13306-13311
17. Mutirangura A., Charuruks N., Shuangshoti S., Sakdikul S., Chatsantikul R., Pornthanakasem W., et al. Identification of distinct regions of allelic loss on chromosome 13q in nasopharyngeal cancer from paraffin embedded tissues. Int. J. Cancer 83 (1999) 210-214
18. Vahakangas K.H., Bennett W.P., Castren K., Welsh J.A., Khan M.A., Blomeke B., et al. P53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res. 61 (2001) 4350-4356
19. Slebos R.J., Hruban R.H., Dalesio O., Mooi W.J., Offerhaus G.J., and Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J. Natl Cancer Inst. 83 (1991) 1024-1027
20. Ahrendt S.A., Decker P.A., Alawi E.A., Zhu Yr Y.R., Sanchez-Cespedes M., Yang S.C., et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92 (2001) 1525-1530
21. Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10 (2004) 8195-8203